Business Wire

ServiceNow Makes No Layoff Pledge for 2020

Share

ServiceNow (NYSE: NOW), the leading digital workflow company that makes work, work better for people, is committing to protect the jobs of its 11,000-plus global workforce through 2020 despite the economic uncertainty of the COVID-19 pandemic. The company also expects to keep hiring for new jobs worldwide this year. In addition, ServiceNow expects to continue to protect the jobs and salaries of several hundred support staff and contractors who are not working while ServiceNow’s offices remain closed.

“We want our employees focused on supporting our customers, not worried about their own jobs,” said Bill McDermott, ServiceNow’s CEO. “We are committed to no layoffs for 2020. We are continuing to hire worldwide.”

“We are grateful to be in this position,” McDermott continued. “Keeping our company strong means we can help our customers succeed. Supporting our customers, we can help get the U.S. and global economy working again. More than ever, companies see that creating great workflow-designed experiences help protect revenue and growth, provide business continuity and drive productivity. These are the priorities for every company now. We are all in this together.”

ServiceNow has continued to hire and onboard new employees throughout the COVID-19 pandemic. The company expects to create and fill more than 1,000 new jobs in the U.S., and more worldwide, by the end of 2020. Additionally, this summer the company will welcome approximately 360 college interns from around the world to work across its business. As a digital workflow company, ServiceNow has been able to quickly pivot to a digital internship program, maintaining the ability to provide college interns valuable career experience, even if employees continue to operate in a work-from-home environment. ServiceNow’s employees worldwide have been working from home since mid-March and expect to continue to do so until June 1.

Caroline Parkinson, a 2021 expected graduate of the University of Michigan who will join ServiceNow’s internship program this summer, said: “ServiceNow saved my summer. Without their digital intern program, I would have had to scramble to find a new summer job. Knowing that ServiceNow is determined to make my internship as enriching as possible during this uncertain time reaffirms my decision to join this company.”

Additionally, ServiceNow, along with Accenture, Lincoln Financial Group, and Verizon, this week announced People+Work Connect, a collaborative online employer-to-employer initiative that will bring together companies with workforces laid off or furloughed due to COVID-19 with those in urgent need of workers. More than 800 ServiceNow jobs will be posted through this collaborative effort. At no charge for employers to join and participate, the initiative is intended to help shorten the complex, lengthy cycle of finding new employment. For more information, visit: https://peopleworkconnect.accenture.com/welcome.

Helping our Customers Respond to COVID-19

ServiceNow is continuing to work aggressively to support its customers during this challenging time, including helping local, state and federal agencies better manage and coordinate emergency response efforts by utilizing ServiceNow’s digital workflow platform technology and no-charge COVID-19 emergency response applications.

Washington State’s Department of Health, a ServiceNow customer, initially created the Emergency Response Operations app on the Now Platform to manage their own response to COVID-19. Working with ServiceNow, the Department of Health has made the app available to all government entities at no charge.

In addition to the State of Washington’s Emergency Response Operations app, ServiceNow recently developed and introduced three, no-charge community apps: Emergency Outreach App, Emergency Self Report App and Emergency Exposure Management app. These community apps are part of a broader Customer Care Plan launched by ServiceNow in March to support its customers as they focus on maintaining business operations during the COVID-19 pandemic.

Examples of organizations leveraging ServiceNow to support their COVID-19 efforts include:

  • The City of Los Angeles, which was able to implement drive-through COVID-19 testing using the Now Platform. Within 48 hours of deployment, the City pushed their portal live to 16 million citizens who can now research and verify symptoms, schedule an appointment and choose a drive-through testing location.
  • The Calgary Catholic School District, which used the Now Platform to enable staff with links to critical information for a seamless, rapid transition from teaching in the classroom to educating from home. This continued student learning was made possible because of the simplified employee experience made available to their teacher.
  • A US retail company, that was able to rapidly respond to the influx of human resources cases for emergency paid leave requests due to COVID-19 by using the Now Platform. Within 96 hours, a mobile application was built and deployed to 330,000 employees globally.
  • A large City in the U.S., which deployed an application on the Now Platform to assist 1.8 million of its citizens in need of food and distribution of other necessities during the COVID-19 pandemic.

“We deeply believe that technology should be in the service of people, and right now that means our responsibility is to help flatten the curve and aid other global organizations in continuing their own valuable work, employment and growth of their workforces,” McDermott said. “ServiceNow is committed to relentless innovation and protecting and creating jobs, to help us all emerge from this pandemic as a stronger community.”

More information about ServiceNow’s customer care plan, including accessing the community apps, can be found at servicenow.com/crisisresponse.

ServiceNow and its employees also have committed $1.5 million in cash donations to help COVID-19 response efforts. ServiceNow will make $1.225 million in corporate grants to the United Nations Foundation; the Centers for Disease Control Foundation; the NYC Mayor’s COVID-19 Emergency Relief Fund; the Silicon Valley Community Foundation COVID-19 Coronavirus Response Funds; and Second Harvest of Silicon Valley. Employee matching gift campaigns will raise additional funds to benefit non-profits in the local communities where our employees live and work.

Forward-Looking Statements

This press release contains forward‑looking statements relating to ServiceNow’s headcount, hiring and workforce expectations and plans. Such forward‑looking statements include, but are not limited to, statements that contain words such as expects, intends, aims or similar words conveying that the information is not historical fact. These statements reflect the current beliefs of ServiceNow and are based on current information available to ServiceNow as of the date hereof. Forward‑looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual outcomes and results to differ materially from those expected or implied by the forward‑looking statements. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our outcomes and results could differ materially from the those expressed or implied by the forward-looking statements ServiceNow makes. Factors that may cause actual outcomes and results to differ materially from those in any forward-looking statements include, without limitation, changes to global economic conditions and changes in the severity of the COVID-19 pandemic and its impact on our customers, partners or vendors. ServiceNow undertakes no obligation, and does not intend, to update these forward-looking statements after the date on which they are made.

About ServiceNow

ServiceNow (NYSE: NOW) is making the world of work, work better for people. Our cloud‑based platform and solutions deliver digital workflows that create great experiences and unlock productivity for employees and the enterprise. For more information, visit: www.servicenow.com.

© 2020 ServiceNow, Inc. All rights reserved. ServiceNow, the ServiceNow logo, Now, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries. Other company names, product names, and logos may be trademarks of the respective companies with which they are associated.

Contact information

ServiceNow PR
Penny Bruce
(408) 893-0601
penelope.bruce@servicenow.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 21:31:00 EESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leuke

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 14:57:00 EESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom